MCRB News and Press, Seres Therapeutics Inc. From 01/30/24

2024-01-30 05:15:11 ET Summary Seres Therapeutics focuses on microbiome therapies, with its leading product VOWST preventing recurrent Clostridioides difficile infection. The company is developing SER-155, which has FDA Fast Track Designation, and has other products in its pipelin...

2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...

2024-01-09 10:16:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Seres Therapeutics Inc (NASDAQ: MCRB), Sentage Holdings (NASDAQ: SNTG), Precision BioSciences Inc (NASDAQ: DTI...

2024-01-09 08:51:09 ET More on Seres Therapeutics Seres Therapeutics: Much Better Risk-Reward At Current Price, But Still Risky Seres Therapeutics: Evaluating Vowst's Market Challenges (Rating Downgrade) Seeking Alpha’s Quant Rating on Seres Therapeutics ...

2024-01-09 08:06:58 ET DENVER, Colo., Jan. 9, 2023 ( www.247marketnews.com )- Seres Therapeutics, Inc. (NASDAQ: MCRB) announced, this morning, preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its ...

VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023 Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts SER-155 ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT. An audio webcast of...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented a...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of the presentation will be av...

2023-11-27 11:23:02 ET Summary SunPower is a Seeking Alpha Quant “strong sell,” with 36.9% of the shares shorted. SunPower is majority-owned (50.7%) by TotalEnergies and it has a strong presence in the US domestic solar and energy management scene. Notwithstandin...